Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury

被引:30
|
作者
Weaver, Richard J. [1 ]
Betts, Catherine [2 ]
Blomme, Eric A. G. [3 ]
Gerets, Helga H. J. [4 ]
Jensen, Klaus Gjervig [5 ]
Hewitt, Philip G. [6 ]
Juhila, Satu [7 ]
Labbe, Gilles [8 ]
Liguori, Michael J. [3 ]
Mesens, Natalie [9 ]
Ogese, Monday O. [10 ]
Persson, Mikael [11 ]
Snoeys, Jan [12 ]
Stevens, James L. [13 ]
Walker, Tracy [14 ]
Park, B. Kevin [15 ]
机构
[1] Inst Rech Int Servier, Res & Biopharm, Suresnes, France
[2] AstraZeneca R&D, Pathol Sci Drug Safety & Metab, Cambridge, England
[3] AbbVie, Preclin Safety, N Chicago, IL USA
[4] UCB BioPharma SPRL, Non Clin Dev, Chemin Foriest, Braine Lalleud, Belgium
[5] H Lundbeck & Co AS, Drug ADME Res, 9 Ottiliavej, Valby, Denmark
[6] Merck KGaA, Nonclin Dev, Darmstadt, Germany
[7] Orion Pharma, In Vitro Biol, Espoo, Finland
[8] Sanofi R&D, Invest Toxicol, Preclin Safety, Paris, France
[9] Janssen, Preclin Dev & Safety, Turnhoutseweg 30, Beerse, Belgium
[10] AstraZeneca R&D, Pathol Sci Drug Safety & Metab, Cambridge, England
[11] AstraZeneca R&D, Discovery Safety, Drug Safety & Metab, Innovat Med & Early Clin Dev, Molndal, Sweden
[12] Janssen, Pharmacokinet Dynam & Metab, Turnhoutseweg 30, Beerse, Belgium
[13] Eli Lilly & Co, Lilly Res Labs, Dept Toxicol, Indianapolis, IN 46285 USA
[14] GlaxoSmithKline, David Jack Ctr Res & Dev, Invest Safety & Drug Metab, Ware, Herts, England
[15] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England
关键词
Human; hepatocytes; HepaRG; HepG2; DILI; liver; drug discovery; drug development; hepatobiliary; cytotoxicity; mitochondrial toxicity; cholestasis; immune system; IMI; test systems; endpoints; IN-VITRO; MITOCHONDRIAL TOXICITY; HEPG2; CELLS; PREDICTIVE TOXICOLOGY; MECHANISTIC ASSAYS; CHO-CELLS; T-CELLS; MODELS; HEPATOTOXICITY; MICE;
D O I
10.1080/17425255.2017.1341489
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: The liver is an important target for drug-induced toxicities. Early detection of hepatotoxic drugs requires use of well-characterized test systems, yet current knowledge, gaps and limitations of tests employed remains an important issue for drug development. Areas Covered: The current state of the science, understanding and application of test systems in use for the detection of drug-induced cytotoxicity, mitochondrial toxicity, cholestasis and inflammation is summarized. The test systems highlighted herein cover mostly in vitro and some in vivo models and endpoint measurements used in the assessment of small molecule toxic liabilities. Opportunities for research efforts in areas necessitating the development of specific tests and improved mechanistic understanding are highlighted. Expert Opinion: Use of in vitro test systems for safety optimization will remain a core activity in drug discovery. Substantial inroads have been made with a number of assays established for human Drug-induced Liver Injury. There nevertheless remain significant gaps with a need for improved in vitro tools and novel tests to address specific mechanisms of human Drug-Induced Liver Injury. Progress in these areas will necessitate not only models fit for application, but also mechanistic understanding of how chemical insult on the liver occurs in order to identify translational and quantifiable readouts for decision-making.
引用
收藏
页码:767 / 782
页数:16
相关论文
共 50 条
  • [1] Drug-induced liver injury: Mechanisms and test systems
    Bissell, DM
    Gores, GJ
    Laskin, DL
    Hoofnagle, JH
    [J]. HEPATOLOGY, 2001, 33 (04) : 1009 - +
  • [2] The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development
    Walker, Paul A.
    Ryder, Stephanie
    Lavado, Andrea
    Dilworth, Clive
    Riley, Robert J.
    [J]. ARCHIVES OF TOXICOLOGY, 2020, 94 (08) : 2559 - 2585
  • [3] The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development
    Paul A. Walker
    Stephanie Ryder
    Andrea Lavado
    Clive Dilworth
    Robert J. Riley
    [J]. Archives of Toxicology, 2020, 94 : 2559 - 2585
  • [4] Rechallenge in drug-induced liver injury: the attractive hazard
    Andrade, Raul J.
    Robles, Mercedes
    Lucena, Maria Isabel
    [J]. EXPERT OPINION ON DRUG SAFETY, 2009, 8 (06) : 709 - 714
  • [5] Causality Assessment in Drug-Induced Liver Injury
    Hayashi, Paul H.
    [J]. SEMINARS IN LIVER DISEASE, 2009, 29 (04) : 348 - 356
  • [6] A drug for drug-induced liver injury?
    不详
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (03) : 177 - 177
  • [7] Managing the Risk of Drug-Induced Liver Injury
    Watkins, P. B.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (06) : 629 - 631
  • [8] Drug-Induced Hepatotoxicity or Drug-Induced Liver Injury
    Pugh, Aaron J.
    Barve, Ashutosh J.
    Falkner, Keith
    Patel, Mihir
    McClain, Craig J.
    [J]. CLINICS IN LIVER DISEASE, 2009, 13 (02) : 277 - +
  • [9] Drug-induced liver injury: recent advances in diagnosis and risk assessment
    Kullak-Ublick, Gerd A.
    Andrade, Raul J.
    Merz, Michael
    End, Peter
    Benesic, Andreas
    Gerbes, Alexander L.
    Aithal, Guruprasad P.
    [J]. GUT, 2017, 66 (06) : 1154 - 1164
  • [10] Risk assessment of drug-induced liver injury based on in vitro covalent binding to human liver proteins
    Usui, Toru
    Mise, Masashi
    Hashizume, Takanori
    Yabuki, Masashi
    Komuro, Setsuko
    [J]. DRUG METABOLISM REVIEWS, 2009, 41 : 125 - 125